Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody
Daratumumab is a monoclonal immunoglobulin against CD38 and has been approved for treating patients with refractory multiple myeloma. The presence of daratumumab in the sera can interfere with pretransfusion testing due to the weakly expression of CD38 on red cells. The reactivity could be mistaken...
שמור ב:
| Principais autores: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| סדרה: | Asian Journal of Transfusion Science |
| נושאים: | |
| גישה מקוונת: | http://www.ajts.org/article.asp?issn=0973-6247;year=2017;volume=11;issue=2;spage=209;epage=211;aulast=Lin |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|